The PBS listing of pembrolizumab (Keytruda) is being extended for the treatment of melanoma. From 1 September pembrolizumab will be available through the PBS as adjuvant treatment for patients who have had completely surgically resected Stage IIIB, IIIC or IIID malignant melanoma. The expanded listing is expected to widen access for about 2,000 eligible patients each ...
Expanded PBS access to pembrolizumab
1 Sep 2020